Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
0.00% $17.51
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 1 099.06 mill |
EPS: | -5.31 |
P/E: | -3.30 |
Earnings Date: | May 07, 2024 |
SharesOutstanding: | 62.77 mill |
Avg Daily Volume: | 0.983 mill |
RATING 2024-03-28 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Sell | |
Return On Asset: | Sell | |
DE: | Neutral | |
P/E: | Strong Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | ||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -3.30 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.56x |
Company: PE -3.30 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$1.790 (-89.78%) $-15.72 |
Date: 2024-03-29 |
Expected Trading Range (DAY) |
---|
$ 16.19 - 18.83 ( +/- 7.56%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-12 | Tousignant Jennifer | Buy | 0 | |
2024-02-12 | Tousignant Jennifer | Buy | 290 000 | Stock Option (Right to Buy) |
2024-02-05 | Ciulla Thomas | Buy | 50 000 | Stock Option (Right to Buy) |
2024-01-22 | Fairmount Funds Management Llc | Buy | 476 190 | Common Stock |
2024-01-03 | Ciulla Thomas | Sell | 0 | Common Stock |
INSIDER POWER |
---|
59.35 |
Last 95 transactions |
Buy: 5 615 027 | Sell: 1 533 788 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $17.51 (0.00% ) |
Volume | 0.940 mill |
Avg. Vol. | 0.983 mill |
% of Avg. Vol | 95.68 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $17.81 | N/A | Active |
---|
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.